Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction
The findings suggest that empagliflozin is a cost-effective treatment option for the Malaysian HF population, including those with EF>40%. As such, the intervention warrants consideration by the Malaysian healthcare provider to mitigate the burden of HF and address the unmet needs of the EF>40% population.
Authors
- Stephan Linden (ORCID: https://orcid.org/0000-0002-2106-1799)
- Siew Chin Ong (ORCID: https://orcid.org/0000-0002-9750-9588)
- Yi Jing Tan (ORCID: https://orcid.org/0009-0006-5128-4877)
Institutions
- Ministry of Health (MY)
- Boehringer Ingelheim (Germany) (DE)
- Universiti Sains Malaysia (MY)
- Serdang Hospital (MY)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1371/journal.pone.0305257
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.72